Brief: Neovacs: new supply agreement with German group Biosyn to diversify sourcing of KLH
01/04/2019 06:33
April 1 (Reuters) - Neovacs SA ALNEV.PA :
* Signed a new supply agreement with the German company
biosyn GmbH to diversify its sourcing of KLH, one of the three
components required to manufacture its therapeutic vaccine IFNα
Kinoid.
* KLH produced by biosyn GmbH is registered as a bladder
cancer drug in key pharmaceutical markets, including two
European Countries. It is also used as a carrier protein for
conjugated vaccines manufacturing. This raw material is
GMP grade and its regulatory file is regularly updated
((sudip.kargupta@thomsonreuters.com;))
Recent news on Neovacs SA
See all newsBrief: Neovacs And FOCH Hospital Commit To Partnership On Research In Pneumology And Allergology
Brief: Neovacs Presented Latest Results On Its Vaccine Candidates Targeting Allergies
Brief: Neovacs H1 Gross Cash Position Down At EUR 6.2 Mln
Brief: Neovacs: Signature Of Trust Agreement For Equitization Of Bonds Redeemable In Shares With Share Warrants
Brief: Neovacs Launches A Public Offering Of Bonds Redeemable In Shares With Stock Warrants